J Menopausal Med.  2015 Dec;21(3):142-148. 10.6118/jmm.2015.21.3.142.

Serum Anti-Mullerian Hormone Levels before Surgery in Patients with Ovarian Endometriomas Compared to Other Benign Ovarian Cysts

• Jeon JH
• Park SY
• Lee SR
• Jeong K
• Chung HW

• KMID: 2200964
• DOI: http://doi.org/10.6118/jmm.2015.21.3.142

Abstract

OBJECTIVES
To evaluate preoperative anti-Mullerian hormone (AMH) levels in women with endometrioma or other benign ovarian cysts and differences of AMH changes according to various characteristics.
METHODS
Ninety-seven patients aged 20 to 39 years who underwent surgery for benign ovarian cyst were enrolled retrospectively. Of these, 65 patients were diagnosed as endometriomas, and 32 had other benign cysts. Serum AMH, mean, maximum, and total diameter of ovarian cysts were measured. The AMH levels were compared according to pathology (endometrioma vs. other benign cyst), size of ovarian cyst, age-matched AMH quartile percentile and characteristics of endometrioma.
RESULTS
Preoperative serum AMH level was significantly lower in endometrioma group than other benign cyst group (4.12 +/- 2.42 ng/mL vs. 6.02 +/- 2.29 ng/mL, P < 0.001). Serum AMH level was significantly lower in endometrioma group, especially in patients aged 30 to 39 years. Dividing to age-matched AMH quartile percentile, there were significantly fewer patients with AMH level > or = 75 percentile in endometrioma group (24.6% vs. 50.0%, P = 0.035). Among 4 subgroups of endometrioma, patients with AMH level > or = 75 percentile were significantly decreased in multiple bilateral endometrioma group. Mean and total diameter of cysts were negatively correlated with preoperative serum AMH level in other benign cyst group.
CONCLUSION
We suggest that preoperative AMH level measurement might be considered in women with endometrioma, especially in 30 to 39 years old, multiple bilateral type, or big-sized other benign ovarian cyst to assess the diminished ovarian reserve.

Keyword

Anti-Mullerian hormone; Endometriosis; Ovarian cysts; Ovarian reserve

MeSH Terms

Anti-Mullerian Hormone*
Endometriosis*
Female
Humans
Ovarian Cysts*
Pathology
Retrospective Studies
Anti-Mullerian Hormone

Reference

1. Kim CR, Ku CH, Jeon IS, Son DW, Lee JS. The clinicopathologic features and significance of preoperative CA 125 in patients who had an operation for ovarian tumors. J Korean Soc Menopause. 2013; 19:26–35.

2. Park JW, Hwang SO, Park JH, Lee BI, Lee JH, Kim KW, et al. Discrimination between benign and malignant pelvic masses using the risk of malignancy index 1. J Korean Soc Menopause. 2013; 19:18–25.

3. ACOG Committee on Practice Bulletins. ACOG practice bulletin. Medical management of endometriosis. Number 11, December 1999 (replaces Technical Bulletin Number 184, September 1993). Clinical management guidelines for obstetrician-gynecologists. Int J Gynaecol Obstet. 2000; 71:183–196.

4. Mun MJ, Kim JH, Kim TH, Hwang JY, Jang WC. Associations between estrogen receptor gene polymorphisms and endometriosis. J Korean Soc Menopause. 2013; 19:64–73.

5. D'Hooghe TM, Debrock S, Hill JA, Meuleman C. Endometriosis and subfertility: is the relationship resolved? Semin Reprod Med. 2003; 21:243–254.

6. Benaglia L, Somigliana E, Vercellini P, Abbiati A, Ragni G, Fedele L. Endometriotic ovarian cysts negatively affect the rate of spontaneous ovulation. Hum Reprod. 2009; 24:2183–2186.

7. The American Fertility Society. Classification of endometriosis. Fertil Steril. 1979; 32:633–634.

8. Gleicher N, Weghofer A, Barad DH. Defining ovarian reserve to better understand ovarian aging. Reprod Biol Endocrinol. 2011; 9:23.

9. Sills ES, Alper MM, Walsh AP. Ovarian reserve screening in infertility: practical applications and theoretical directions for research. Eur J Obstet Gynecol Reprod Biol. 2009; 146:30–36.

10. Al-Azemi M, Killick SR, Duffy S, Pye C, Refaat B, Hill N, et al. Multi-marker assessment of ovarian reserve predicts oocyte yield after ovulation induction. Hum Reprod. 2011; 26:414–422.

11. Shin SY, Lee JR, Noh GW, Kim HJ, Kang WJ, Kim SH, et al. Analysis of serum levels of anti-Mullerian hormone, inhibin B, insulin-like growth factor-I, insulin-like growth factor binding protein-3, and follicle-stimulating hormone with respect to age and menopausal status. J Korean Med Sci. 2008; 23:104–110.

12. La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC, et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010; 16:113–130.

13. Cate RL, Mattaliano RJ, Hession C, Tizard R, Farber NM, Cheung A, et al. Isolation of the bovine and human genes for Müllerian inhibiting substance and expression of the human gene in animal cells. Cell. 1986; 45:685–698.

14. Toner JP, Seifer DB. Why we may abandon basal follicle-stimulating hormone testing: a sea change in determining ovarian reserve using antimullerian hormone. Fertil Steril. 2013; 99:1825–1830.

15. Shebl O, Ebner T, Sommergruber M, Sir A, Tews G. Anti muellerian hormone serum levels in women with endometriosis: a case-control study. Gynecol Endocrinol. 2009; 25:713–716.

16. Campos CS, Vaamonde D, Andreoli C, Martins AC, Genro VK, Souza CA, et al. Follicular-fluid anti-Müllerian hormone concentration is similar in patients with endometriosis compared with non-endometriotic patients. Reprod Biomed Online. 2010; 21:470–473.

17. Pacchiarotti A, Frati P, Milazzo GN, Catalano A, Gentile V, Moscarini M. Evaluation of serum anti-Mullerian hormone levels to assess the ovarian reserve in women with severe endometriosis. Eur J Obstet Gynecol Reprod Biol. 2014; 172:62–64.

18. Yoo JH, Kim HO, Cha SW, Park CW, Yang KM, Song IO, et al. Age specific serum anti-Müllerian hormone levels in 1,298 Korean women with regular menstruation. Clin Exp Reprod Med. 2011; 38:93–97.

19. Kitajima M, Defrère S, Dolmans MM, Colette S, Squifflet J, Van Langendonckt A, et al. Endometriomas as a possible cause of reduced ovarian reserve in women with endometriosis. Fertil Steril. 2011; 96:685–691.

20. Zhang X, Li XH, Ma X, Wang ZH, Lu S, Guo YL. Redoxinduced apoptosis of human oocytes in resting follicles in vitro. J Soc Gynecol Investig. 2006; 13:451–458.

21. Halis G, Arici A. Endometriosis and inflammation in infertility. Ann N Y Acad Sci. 2004; 1034:300–315.

22. Stilley JA, Birt JA, Sharpe-Timms KL. Cellular and molecular basis for endometriosis-associated infertility. Cell Tissue Res. 2012; 349:849–862.

23. Gupta S, Goldberg JM, Aziz N, Goldberg E, Krajcir N, Agarwal A. Pathogenic mechanisms in endometriosis-associated infertility. Fertil Steril. 2008; 90:247–257.

24. de Vet A, Laven JS, de Jong FH, Themmen AP, Fauser BC. Antimullerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril. 2002; 77:357–362.

25. Lee MM, Donahoe PK, Hasegawa T, Silverman B, Crist GB, Best S, et al. Mullerian inhibiting substance in humans: normal levels from infancy to adulthood. J Clin Endocrinol Metab. 1996; 81:571–576.

26. Kaya C, Pabuccu R, Satiroglu H. Serum antimüllerian hormone concentrations on day 3 of the in vitro fertilization stimulation cycle are predictive of the fertilization, implantation, and pregnancy in polycystic ovary syndrome patients undergoing assisted reproduction. Fertil Steril. 2010; 94:2202–2207.

27. La Marca A, Broekmans FJ, Volpe A, Fauser BC, Macklon NS. Anti-Mullerian hormone (AMH): what do we still need to know? Hum Reprod. 2009; 24:2264–2275.

28. Chang HJ, Han SH, Lee JR, Jee BC, Lee BI, Suh CS, et al. Impact of laparoscopic cystectomy on ovarian reserve: serial changes of serum anti-Müllerian hormone levels. Fertil Steril. 2010; 94:343–349.

29. Streuli I, de Ziegler D, Gayet V, Santulli P, Bijaoui G, de Mouzon J, et al. In women with endometriosis anti-Mullerian hormone levels are decreased only in those with previous endometrioma surgery. Hum Reprod. 2012; 27:3294–3303.

30. Somigliana E, Benaglia L, Vigano P, Candiani M, Vercellini P, Fedele L. Surgical measures for endometriosis-related infertility: a plea for research. Placenta. 2011; 32:Suppl 3. S238–S242.

31. de Carvalho BR, Rosa-e-Silva AC, Rosa-e-Silva JC, dos Reis RM, Ferriani RA, de Sá MF. Anti-müllerian hormone is the best predictor of poor response in ICSI cycles of patients with endometriosis. Clin Exp Obstet Gynecol. 2011; 38:119–122.

32. Falconer H, Sundqvist J, Gemzell-Danielsson K, von Schoultz B, D'Hooghe TM, Fried G. IVF outcome in women with endometriosis in relation to tumour necrosis factor and Anti-Müllerian hormone. Reprod Biomed Online. 2009; 18:582–588.

33. Papaleo E, Ottolina J, Vigano P, Brigante C, Marsiglio E, De Michele F, et al. Deep pelvic endometriosis negatively affects ovarian reserve and the number of oocytes retrieved for in vitro fertilization. Acta Obstet Gynecol Scand. 2011; 90:878–884.